Clinical practice guideline for #NephJC?
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
Why does the CKD screening matters? Because of this: http://t.co/HKuUTJgZvR @NephJC #nephJC
— Xavier F. Vela (@xaviervel) May 6, 2014
Though not a tradition subject for journal club, it seems that clinical practice guidelines have an important role in today’s practice (1/2)
— Joel Topf (@kidney_boy) May 5, 2014
I propose the new hyponatremia guidelines for #NephJC http://t.co/hNGxibmNfy (2/2)
— Joel Topf (@kidney_boy) May 5, 2014
What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?
Chronic kidney disease blast Central America: http://t.co/7Yxkf8uMfb #renalweek #kidneyweek #NephJC pic.twitter.com/4XyXCbkzma
— Xavier F. Vela (@xaviervel) May 1, 2014
Latest hope for DN: endothelin antagonists http://t.co/64hQ0rs5xX one for #NephJC? @NephJC @kidney_boy
— Paul Phelan (@paulphel) April 23, 2014
http://t.co/siLrMR1v7i Time for routine kidney biopsy in all patients (not just the risk ones) with suspected GN? Paper for #NephJC ?
— ChristosArgyropoulos (@ChristosArgyrop) April 23, 2014
Prenatal risk factors for childhood CKD in JASN -- a possible peg article for #NephJC? http://t.co/t7hmG91XXS
— NatureRevNephrology (@NatRevNeph) April 25, 2014
Atrasentan lowers residual albuminuria T2DM, but ... "manageable" fluid-overload. #NephJC #CJASN http://t.co/G5C6FT5PSu
— Ernesto LopezAlmaraz (@kidney_doctor) April 29, 2014